Lit Matters 2: Should We Prescribe Inhaled Corticosteroids from the ED?

Inhaled corticosteroids are guideline-level therapy for asthma, yet they are rarely prescribed at ED discharge. In adults discharged after an asthma visit, outpatient follow-up is poor, making the emergency department a critical place to start disease-modifying treatment rather than relying on later primary care.

ED Asthma Discharge Prescribing

• Guideline standard of care: GINA recommends inhaled corticosteroids across asthma treatment tracks, including intermittent disease, so there is effectively no evidence-based outpatient path that skips ICS.
• Low discharge prescription rate: Despite that standard, ICS were prescribed in only 6% of ED asthma discharges in this cohort, a gap that becomes more concerning when follow-up after the visit is uncommon.
• Poor outpatient follow-up: Only about 14% of asthma ED visits were followed by an outpatient visit within 30 days, which strengthens the case for starting controller therapy before the patient leaves the department.
• Strongest prescribing predictor: Receiving an ICS during the ED stay was the clearest predictor of getting an ICS at discharge, with an odds ratio near 10. We get into the practical prescribing implications in the episode.
• Controller over rescue framing: ICS are not just symptom relief add-ons; they reduce airway inflammation, improve beta-receptor responsiveness, and help other asthma therapies work better.
• Combination inhaler caution: ICS-formoterol is an attractive discharge option for some patients, but long-acting beta-agonists should not be prescribed without an inhaled corticosteroid.

Safety, Cost, and Practical Barriers

• Minimal systemic steroid effect: Inhaled corticosteroids have essentially minimal systemic effects because most deposited drug stays in the lungs or undergoes first-pass metabolism after swallowing.
• Expected adverse effects: The main downsides are local effects such as hoarseness, thrush, and contact dermatitis, which is a very different risk profile from prolonged systemic steroid exposure.
• Cost and access friction: Out-of-pocket pricing varies widely across inhalers, and that cost spread likely contributes to under-prescribing and nonadherence more than pharmacology does in many ED patients.
• Primary care handoff myth: Deferring ICS initiation to primary care sounds tidy, but with only about half of patients having a documented PCP, that handoff is often more theoretical than real.